Literature DB >> 8506281

A proposal for a new approach to a preventive vaccine against human immunodeficiency virus type 1.

H M Temin1.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) is a more complex retrovirus, coding for several accessory proteins in addition to the structural proteins (Gag, Pol, and Env) that are found in all retroviruses. More complex retroviruses have not been isolated from birds, and simpler retroviruses have not been isolated from humans. However, the proviruses of many endogenous simpler retroviruses are present in the human genome. These observations suggest that humans can mount a successful protective response against simpler retroviruses, whereas birds cannot. Thus, humans might be able to mount a successful protective response to infection with a simpler HIV-1. As a model, a simpler bovine leukemia virus which is capable of replicating has been constructed; a simpler HIV-1 could be constructed in a similar fashion. I suggest that such a simpler HIV-1 would be a safe and effective vaccine against HIV-1.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8506281      PMCID: PMC46522          DOI: 10.1073/pnas.90.10.4419

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  28 in total

Review 1.  Human endogenous proviruses.

Authors:  E Larsson; N Kato; M Cohen
Journal:  Curr Top Microbiol Immunol       Date:  1989       Impact factor: 4.291

2.  Isolation of three kinds of human endogenous retrovirus-like sequences using tRNA(Pro) as a probe.

Authors:  F Harada; N Tsukada; N Kato
Journal:  Nucleic Acids Res       Date:  1987-11-25       Impact factor: 16.971

3.  Human serum lyses RNA tumour viruses.

Authors:  R M Welsh; N R Cooper; F C Jensen; M B Oldstone
Journal:  Nature       Date:  1975-10-16       Impact factor: 49.962

4.  A novel human nonviral retroposon derived from an endogenous retrovirus.

Authors:  M Ono; M Kawakami; T Takezawa
Journal:  Nucleic Acids Res       Date:  1987-11-11       Impact factor: 16.971

5.  Human endogenous retroviruslike genome with type C pol sequences and gag sequences related to human T-cell lymphotropic viruses.

Authors:  D L Mager; J D Freeman
Journal:  J Virol       Date:  1987-12       Impact factor: 5.103

6.  A new class of endogenous human retroviral genomes.

Authors:  R Callahan; I M Chiu; J F Wong; S R Tronick; B A Roe; S A Aaronson; J Schlom
Journal:  Science       Date:  1985-06-07       Impact factor: 47.728

7.  Human immunodeficiency virus-like particles produced by a vaccinia virus expression vector.

Authors:  V Karacostas; K Nagashima; M A Gonda; B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

8.  Ancestry of a human endogenous retrovirus family.

Authors:  R Mariani-Costantini; T M Horn; R Callahan
Journal:  J Virol       Date:  1989-11       Impact factor: 5.103

9.  Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene.

Authors:  M D Daniel; F Kirchhoff; S C Czajak; P K Sehgal; R C Desrosiers
Journal:  Science       Date:  1992-12-18       Impact factor: 47.728

10.  Nucleotide sequence of a full-length human endogenous retroviral segment.

Authors:  R Repaske; P E Steele; R R O'Neill; A B Rabson; M A Martin
Journal:  J Virol       Date:  1985-06       Impact factor: 5.103

View more
  13 in total

1.  Continuous propagation of RRE(-) and Rev(-)RRE(-) human immunodeficiency virus type 1 molecular clones containing a cis-acting element of simian retrovirus type 1 in human peripheral blood lymphocytes.

Authors:  A S Zolotukhin; A Valentin; G N Pavlakis; B K Felber
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

2.  In vivo study of genetically simplified bovine leukemia virus derivatives that lack tax and rex.

Authors:  K Boris-Lawrie; V Altanerova; C Altaner; L Kucerova; H M Temin
Journal:  J Virol       Date:  1997-02       Impact factor: 5.103

3.  Bovine leukemia virus structural gene vectors are immunogenic and lack pathogenicity in a rabbit model.

Authors:  L Kucerova; V Altanerova; C Altaner; K Boris-Lawrie
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

4.  Long-term infection with retroviral structural gene vector provides protection against bovine leukemia virus disease in rabbits.

Authors:  Veronika Altanerova; Dana Holicova; Lucia Kucerova; Cestmir Altaner; Michael D Lairmore; Kathleen Boris-Lawrie
Journal:  Virology       Date:  2004-11-24       Impact factor: 3.616

5.  A small element from the Mason-Pfizer monkey virus genome makes human immunodeficiency virus type 1 expression and replication Rev-independent.

Authors:  M Bray; S Prasad; J W Dubay; E Hunter; K T Jeang; D Rekosh; M L Hammarskjöld
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-15       Impact factor: 11.205

6.  Inhibitory activity of the equine infectious anemia virus major 5' splice site in the absence of Rev.

Authors:  W Tan; M Schalling; C Zhao; M Luukkonen; M Nilsson; E M Fenyö; G N Pavlakis; S Schwartz
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

7.  The IDDM-associated solitary retroviral promoters DQ-LTR3 and DQ-LTR13 have a distinct impact on the expression of selected DQB1 genes in different cell lines in vitro.

Authors:  Katrin Krach; Klaus Badenhoop; Ralf R Tönjes
Journal:  Immunogenetics       Date:  2003-10-18       Impact factor: 2.846

8.  Genetic instability of live, attenuated human immunodeficiency virus type 1 vaccine strains.

Authors:  B Berkhout; K Verhoef; J L van Wamel; N K Back
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

9.  Genetically simpler bovine leukemia virus derivatives can replicate independently of Tax and Rex.

Authors:  K Boris-Lawrie; H M Temin
Journal:  J Virol       Date:  1995-03       Impact factor: 5.103

10.  Distribution of human endogenous retrovirus HERV-K genomes in humans and different primates.

Authors:  S Steinhuber; M Brack; G Hunsmann; H Schwelberger; M P Dierich; W Vogetseder
Journal:  Hum Genet       Date:  1995-08       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.